Skip to main content

Table 1 Characteristics of colorectal cancer patients by post-diagnostic aspirin use

From: Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

  Aspirin use in first year after cancer diagnosisa
Yes (n = 2150) No (n = 6241)
Number % Number %
Age
 < 50 13 0.6 432 6.9
 50–59 131 6.1 1113 17.8
 60–69 586 27.3 1973 31.6
 70–79 934 43.4 1876 30.1
 ≥ 80 486 22.6 847 13.6
Gender
 Men 1387 64.5 3287 52.7
Deprivation (fifth)
 1 (most deprived) 447 20.8 1039 16.6
 2 497 23.1 1272 20.4
 3 429 20.0 1263 20.2
 4 412 19.2 1361 21.8
 5 (least deprived) 365 17.0 1305 20.9
Tumour location
 Colon 1493 69.4 4227 67.7
 Rectum/rectosigmoid junction 657 30.6 2014 32.3
Dukes’ stage
 A 597 27.8 1683 27.0
 B 851 39.6 2340 37.5
 C 702 32.7 2218 35.5
Grade
 Well differentiated 82 3.8 203 3.3
 Moderately differentiated 1646 76.6 4796 76.8
 Poorly differentiated 315 14.7 968 15.5
 Missing 107 5.0 274 4.4
Treatment (within six months)
 Surgery 2020 94.0 5908 94.7
 Radiotherapy 192 8.9 679 10.9
 Chemotherapy 472 22.0 2167 34.7
Comorbidity before cancer diagnosis
 Acute myocardial infarction 300 14.0 103 1.7
 Congestive heart failure 135 6.3 94 1.5
 Peripheral vascular disease 145 6.7 80 1.3
 Cerebral vascular accident 162 7.5 141 2.3
 Pulmonary disease 207 9.6 383 6.1
 Peptic ulcer 59 2.7 151 2.4
 Liver disease 6 0.3 25 0.4
 Diabetes 290 13.5 285 4.6
 Renal disease 87 4.0 102 1.6
Statin use after diagnosis 1647 76.6 1490 23.9
  1. aRestricted to patients who survived at least 1 year after diagnosis